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Abstract
Background: Several studies have identified rare genetic variations responsible for many cases of
familial breast cancer but their contribution to total breast cancer incidence is relatively small. More
common genetic variations with low penetrance have been postulated to account for a higher
proportion of the population risk of breast cancer.
Methods and Results: In an effort to identify genes that influence non-familial breast cancer risk,
we tested over 25,000 single nucleotide polymorphisms (SNPs) located within approximately
14,000 genes in a large-scale case-control study in 254 German women with breast cancer and 268
age-matched women without malignant disease. We identified a marker on chromosome 14q24.3-
q31.1 that was marginally associated with breast cancer status (OR = 1.5, P = 0.07). Genotypes for
this SNP were also significantly associated with indicators of breast cancer severity, including
presence of lymph node metastases (P = 0.006) and earlier age of onset (P = 0.01). The association
with breast cancer status was replicated in two independent samples (OR = 1.35, P = 0.05). High-
density association fine mapping showed that the association spanned about 80 kb of the zinc-finger
gene DPF3 (also known as CERD4). One SNP in intron 1 was found to be more strongly associated
with breast cancer status in all three sample collections (OR = 1.6, P = 0.003) as well as with
increased lymph node metastases (P = 0.01) and tumor size (P = 0.01).
Conclusion: Polymorphisms in the 5' region of DPF3 were associated with increased risk of breast
cancer development, lymph node metastases, age of onset, and tumor size in women of European
ancestry. This large-scale association study suggests that genetic variation in DPF3 contributes to
breast cancer susceptibility and severity.
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Background
Breast cancer etiology is a complex process, involving
genes in the multiple stages of carcinogenesis, from initial
cell cycle dysregulation to metastatic potential [1,2].
Approximately ten percent of breast cancer cases occur
within families in which the disease segregates in a Men-
delian fashion. BRCA1 and BRCA2 have been identified to
be responsible for a substantial proportion of familial
breast cancer [3,4]. Other genes involved in the same
DNA double-strand break repair pathway, TP53 [5], ATM
[6], and PTEN [7], are also known to contribute to famil-
ial cases, but are more rare. Such high penetrance germ
line mutations are responsible for less than 10% of all
breast cancer cases. However, genetic variation is esti-
mated to contribute approximately 25% to the popula-
tion risk of breast cancer, likely accounted for by a large
number of yet undiscovered common, low penetrance
alleles [8,9]. It is possible that these low penetrance mark-
ers may be useful in the development of practical prog-
nostic and diagnostic indicators with greater utility in the
general population.
Many candidate gene studies have been performed to
identify the genes that contribute to risk for sporadic
breast cancer [10]. Unfortunately, these efforts have been
largely unsuccessful. Some of the more consistently
reported candidates include variations in metabolizing
enzymes, such as the cytochrome P-450 family [11], N-
acetyltransferases [12], and glutathion-S-transferases [13].
The candidate susceptibility allele CHEK2*1110delC was
shown to confer an increased breast cancer risk [14,15],
which was more recently supported by results obtained in
a large case-control study [16]. In an effort to identify
novel genes involved in breast cancer susceptibility, we
have conducted a large-scale, case-control study using
more than 25,000 SNPs located within approximately
14,000 genes. We previously reported the findings on two
breast cancer candidates identified in this study [17,18].
Herein, we describe variations in intron 1 of DPF3 on
chromosome 14q24.3-q31.1 that are associated with
increased risk of breast cancer, lymph node metastases,
earlier age of diagnosis, and tumor size.
Methods
Subjects and Study Design
The participants in the large-scale association study
(referred to as the discovery sample) were recruited
among patients attending the Frauenklinik Innenstadt,
University of Munich, Germany, and comprised 254
breast cancer cases. At the time of assessment, 94 cases
(37%) displayed positive lymph node status, and 18 cases
(7%) had known distant metastases. Twenty-seven cases
(11%) reported having at least one first- or second-degree
relative with breast cancer. The median age of diagnosis
was 56 yr (range = 23–87 yr). During the same period, 268
controls with a median age of 57 yr (range = 17–88 yr)
were recruited from patients with benign disease being
seen at the clinic. Controls with a reported family history
of breast or ovarian cancer were excluded from the current
study. Both parents of each study participant were
reported to be of German descent.
The participants in the German replication sample were
recruited from the Department of Obstetrics and Gynecol-
ogy, Technical University of Munich, and consisted of 188
cases and 150 controls. Most breast cancer cases were
recruited at pre-operative visits, and the female controls
were recruited from healthy individuals or patients with
non-malignant diagnoses. Median age of diagnosis for
cases was 59 yr (range = 22–87 yr) and median age of con-
trols was 50 yr (range = 19–91 yr). Two participants
reported one parent of non-German, Eastern European
origin; otherwise both parents were of German descent.
The participants in the Australian replication sample were
recruited from the Pathology Department of Gold Coast
Hospital or by the Genomics Research Centre, Southport.
The collection included 180 breast cancer cases with a
median age of diagnosis of 50 yr (range = 24–74 yr). Con-
trols consisted of 180 healthy volunteers without family
history of cancer recruited through the Genomics
Research Centre. Controls were individually age-matched
to cases (± 5 yr) with the median age for controls at 60 yr
(range = 28–94 yr).
All subjects involved in our studies signed a written
informed consent and the institutional ethics committees
of participating institutions approved the experimental
protocols.
SNP Markers, Genotyping, and Resequencing
A set of 25,494 SNPs covering the human genome was
selected from a larger collection of 125,799 experimen-
tally validated polymorphisms [19]. This set includes
SNPs that are located in gene coding regions (within 10 kb
of 13,735 genes annotated in Entrez Gene), have a minor
allele frequencies greater than 0.02 (95% have frequencies
greater than 0.1), and a median inter-marker spacing of 40
kb. SNP annotation was based upon the NCBI dbSNP
database, refSNP build 118 [20]. Genomic annotation
was based on NCBI Genome Build 34. Gene annotation
was based upon Entrez Gene genes for which NCBI was
providing positions on the Mapview FTP site [21].
DNA pools were formed by combining equimolar
amounts of each sample as described elsewhere [22,23].
For SNP assays carried out on pooled DNA, 25 ng of DNA
was used. All PCR and MassEXTEND™ reactions were con-
ducted using standard conditions [23]. Relative allele fre-
quency estimates were derived from calculations based onJournal of Carcinogenesis 2005, 4:13 http://www.carcinogenesis.com/content/4/1/13
Page 3 of 9
(page number not for citation purposes)
the area under the peak of mass spectrometry measure-
ments from four analyte aliquots as described elsewhere
[23]. The same procedure was used for individual geno-
typing except 2.5 ng DNA was used and only one mass
spectrometry measurement was taken. Primers used for
genotyping are presented in Table 1. Sequencing was per-
formed under standard conditions for MassCLEAVE™ [24]
using 5 ng of DNA. For Exon 1, the amplification primers
used were 5'-AACGGCAGAGCACATGTAGTAA-3' and 5'-
ATATTGAAACCACGCGGAATA-3'. For Exon 2, the ampli-
fication primers used were 5'-CTGGGTGTGTTTCAGTCT-
TCC-3' and 5'-CTGGTTTCCCAGACAAGCTG-3'.
Statistical Methods
Tests of association between disease status and each SNP
using pooled DNA were carried out in a similar fashion as
explained elsewhere [25]. Sources of measurement varia-
tion included pool formation, PCR/mass extension, and
chip measurement. When three or more replicate meas-
urements of an allele frequency were available within a
model level, the corresponding variance component was
estimated from the data. Otherwise, the following histor-
ical laboratory averages were used: pool formation = 5.0 ×
10-5, PCR/mass extension = 1.7 × 10-4, and chip measure-
ment = 1.0 × 10-4. Tests of association using individual
genotypes were carried out using a chi-square test of het-
erogeneity based on allele and genotype frequencies.
Selected tests of association involving contingency tables
with rare or missing cells were carried out using Fisher's
exact test. The DerSimonian-Laird random effects meta-
analysis method [26] was used for the analysis of replica-
tion samples to test for the consistency of association
while permitting allele frequencies to differ among collec-
tions. All tests of allele frequencies involving only replica-
tion samples are one-sided, confirming the effect
observed in the discovery sample. P-values were derived
using the log odds of each contrast and their standard
errors. Multiple approaches were explored in an effort to
identify haplotypes demonstrating a stronger association
with disease status than single sites. These included anal-
yses of six SNP haplotypes and subsets thereof using the
coalescent theory-based PHASE v2.0 [27] and the score
method that relies on the EM algorithm [28]. No attempt
was made to correct P-values for multiple testing. Rather,
P-values are provided to compare the relative strength of
association from multiple dependent (e.g. SNPs within
samples) and independent (e.g. SNPs between samples)
sources of information. P-values less than 0.05 are
referred to as statistically significant.
Results
SNP markers associated with breast cancer status were
identified using a three-phased approach. In the first
phase, pools of case and control samples were subjected
to a single PCR reaction and primer extension for each of
the 25,494 SNP assays. Four aliquots of the extension
products were measured. The relative allele frequencies
were compared, and 1,619 SNPs (~5%) with the most
Table 1: Primer sequences used in genotyping.
rs8010957 Forward primer 5'-TGC TGG GAT TAT GAG CCA CT-3'
Reverse primer 5'-GTG TGT CTC CAG TAA AGG GC-3'
Extend primer 5'-AAA ACT CTG CTA CTG GC-3'
rs4307892 Forward primer 5'-GCA AAA TGC TAG TAA ATG GTG-3'
Reverse primer 5'-GAA AAA TGG CAA GCC TTC TG-3'
Extend primer 5'-AGA GCA ATG AAC ACC AAT ATC C-3'
rs1990440 Forward primer 5'-AAG TCA CTA ACC CCA CAC AC-3'
Reverse primer 5'-CCA GGG TGT GTT CTA ATA CG-3'
Extend primer 5'-CGT CAG CAA ATG TGT ACC GA-3'
rs4899445 Forward primer 5'-AGG AGA GTC TGC CCA TTT GA-3'
Reverse primer 5'-AGA AAA CTC ACC TCC CTG AC-3'
Extend primer 5'-AGC CCT CTC CAG GGC CAT GC-3'
rs4378563 Forward primer 5'-GCC GTG TGC ATA TCC TGA TC-3'
Reverse primer 5'-TTA TGG CTT CCT CTC CCT AC-3'
Extend primer 5'-CCT CCA TGC CCT GCT TA-3'
rs12232220 Forward primer 5'-TTA AAA ATA CAA TGA TGG CC-3'
Reverse primer 5'-TCC CGA CCT CAG GTG ATG TG-3'
Extend primer 5'-GAT TAC AGG TAT GAG CCA C-3'Journal of Carcinogenesis 2005, 4:13 http://www.carcinogenesis.com/content/4/1/13
Page 4 of 9
(page number not for citation purposes)
statistically significant associations were selected to be
tested in the second phase. In this phase, allele frequen-
cies were measured in three separate PCR and primer
extension reactions using case and control pools, and
compared as in the first phase. The 74 most significant
SNPs (~5%) from the second phase were selected for indi-
vidual genotyping in the samples that comprised the case
and control pools (Figure 1).
Case-control studies employing tens of thousands of SNPs
in a genome-wide approach using liberal selection criteria
are expected to yield a high proportion of false positive
associations. To determine if the observed association was
a true genetic effect, the 74 SNPs were subsequently geno-
typed in two additional breast cancer case-control collec-
tions. After reviewing the results of all three samples, one
significant result was observed for a C-to-G SNP,
rs1990440, in intron 1 of the DPF3 gene on chromosome
14q24.3-q31.1. The frequency of the G allele in discovery
control subjects was 0.08, similar to the NCBI reported
average allele frequency [29]. The frequency was increased
by 4% in the cases. Table 2 shows the association of
rs1990440 with breast cancer in the discovery and two
replication collections. Even though this SNP was only
marginally associated in the German discovery sample
(OR = 1.49, P = 0.069), German replication sample (OR =
1.33, P = 0.29), and Australian replication sample (OR =
1.36, P = 0.22), the estimated effects were consistent and
the analysis of all three samples resulted in a combined
significance of P = 0.016 (OR = 1.40) and a significance of
P  = 0.054 (OR = 1.35) within the replication samples
only.
To fine map the region of association, we tested an addi-
tional 394 SNPs located within the DPF3 gene using the
discovery case and control pools (Figure 2). We observed
that the contiguous region of highest significance
extended approximately 65 kb, spanning the 3' region of
intron 1 with additional evidence for a 15 kb region that
includes exon 2 and a part of intron 2. Using a cleavage
assay and mass spectrometry [24], we re-sequenced exons
1 and 2 with their flanking intron sequences in six breast
cancer cases and five controls to determine if any addi-
tional SNPs with stronger disease association or apparent
functional relevance could be discovered. We identified
only one SNP in intron 1 that was not publicly annotated
(data not shown) and found to have an average allele fre-
quency that did not significantly differ between the case
and control pools. No previously described SNPs reside in
exon 1 or 2, and no novel SNPs were discovered by our
efforts. We selected five SNPs with allele frequencies that
differed significantly between case and control pools,
roughly distanced 20 kb apart, for genotyping in the dis-
covery and replication samples and for further analysis
(Table 1, 2). The SNPs most strongly associated in the dis-
covery and replication samples, rs4307892, rs4899445
and rs4378563, were flanking the original marker SNP
and were in strong linkage disequilibrium (all |D'| > 0.9,
r2 > 0.7). Of the additional SNPs genotyped, rs4899445
demonstrated the most consistent differences between
cases and controls, with a slightly larger effect in the dis-
covery sample (OR = 1.56, P = 0.045) and a substantially
more consistent effect in the German (OR = 1.72, P =
0.094) and Australian (OR = 1.47, P = 0.16) replication
samples (Table 2). The effect of the combined replication
sample was significant at the 0.05 level (OR = 1.56, P =
0.016) and equal to the estimate from all three samples
(OR = 1.56, P = 0.003). Analyses of haplotypes consisting
of subsets of the six genotyped SNPs did not reveal any
haplotype with stronger association than individual SNPs
(data not shown).
The data collected on the patients in the German discov-
ery collection included information on family history of
breast cancer, age of onset, and disease severity. Further
analysis revealed associations between the initial marker
SNP, rs1990440, and multiple traits indicative of cancer
aggressiveness (Table 3), including lower mean age of
Univariate distributions of summary statistics of the 74 geno- typed SNP assays Figure 1
Univariate distributions of summary statistics of the 74 geno-
typed SNP assays. Empirical densities (histograms) are pro-
vided for A) the minor allele frequency in the controls, B) the 
odds ratios (ORs) on a log2 scale presenting the fold-change 
comparing allele frequencies between cases and controls, and 
C) the P-values from the tests of association.
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Table 2: Distribution of genotype counts and relative allele frequencies of the DPF3 polymorphisms1 in breast cancer and control 
groups for discovery and replication samples.
Study Na Genotype count (%) MAFb ORc P-valued
rs8010957 (Intron 1 G>A) AA AG GG A
German2 Case 235 0 (0) 8 (3) 227 (97) 2% 0.34 0.006
Control 256 0 (0) 23 (9) 233 (91) 5%
German3 Case 182 0 (0) 9 (5) 173 (95) 2% 0.94 0.912
Control 134 0 (0) 7 (5) 127 (95) 3%
Australian Case 163 0 (0) 5 (3) 158 (97) 2% 0.62 0.407
Control 164 0 (0) 8 (5) 156 (95) 2%
Replication only 0.79 0.270
Total (all of centres) 0.55 0.058
rs4307892 (Intron 1 G>A) AA AG GG A
German2 Case 238 2 (1) 59 (25) 177 (74) 13% 1.56 0.030
Control 252 1 (0) 44 (17) 213 (83) 9%
German3 Case 185 1 (1) 40 (22) 144 (78) 11% 1.44 0.177
Control 141 2 (1) 19 (13) 120 (85) 8%
Australian Case 173 0 (0) 33 (19) 140 (81) 10% 1.23 0.445
Control 171 1 (1) 25 (15) 145 (85) 8%
Replication only 1.33 0.068
Total (all of centres) 1.43 0.010
rs19904404 (Intron 1 C>G) GG GC CC G
German2 Case 206 2 (1) 46 (22) 158 (77) 12% 1.49 0.069
Control 253 2 (1) 39 (15) 212 (84) 8%
German3 Case 191 1 (1) 39 (20) 151 (79) 11% 1.33 0.286
Control 145 1 (1) 22 (15) 122 (84) 8%
Australian Case 179 1 (2) 34 (19) 144 (80) 11% 1.36 0.224
Control 171 1 (1) 25 (15) 145 (85) 8%
Replication only 1.35 0.054
Total (all of centres) 1.40 0.016
rs4899445 (Intron 1 A>G) GG GA AA G
German2 Case 240 2 (1) 48 (20) 190 (79) 11% 1.56 0.045
Control 257 1 (0) 35 (14) 221 (86) 7%
German3 Case 185 2 (1) 28 (15) 155 (84) 9% 1.72 0.094
Control 143 0 (0) 15 (10) 128 (90) 5%
Australian Case 176 1 (1) 33 (19) 142 (81) 10% 1.47 0.160
Control 172 1 (1) 22 (13) 149 (87) 7%
Replication only 1.56 0.016
Total (all of centres) 1.56 0.003
rs4378563 (Intron 1 C>T) TT CT CC T
German2 Case 235 2 (1) 58 (25) 175 (74) 13% 1.86 0.004
Control 252 2 (1) 34 (13) 216 (86) 8%
German3 Case 175 1 (1) 30 (17) 144 (82) 9% 1.15 0.624
Control 131 1 (1) 19 (15) 111 (85) 8%
Australian Case 162 1 (1) 30 (19) 131 (81) 10% 1.20 0.506
Control 167 1 (1) 26 (16) 140 (84) 8%
Replication only 1.18 0.210
Total (all of centres) 1.44 0.027Journal of Carcinogenesis 2005, 4:13 http://www.carcinogenesis.com/content/4/1/13
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diagnosis of breast cancer (P = 0.01) and lymph node
metastases (P = 0.006). Associations with organ metas-
tases (P = 0.35) and tumor size (P = 0.17) were not statis-
tically significant. The SNP most strongly associated with
breast cancer risk across all three samples, rs4899445, was
also found to be significantly associated with lymph node
metastases (P = 0.008), and increased tumor size (P =
0.007). Though not statistically significant, the risk allele
carriers tended to be younger at age of diagnosis (P = 0.35)
and to have a higher proportion of breast cancer family
history (P = 0.13).
Discussion
Here, we report variants in DPF3, identified through a
large-scale, genome-wide association study, that are asso-
ciated with increased breast cancer risk, lymph node
rs12232220 (Intron 2 G>A) AA AG GG A
German2 Case 237 0 (0) 16 (7) 221 (93) 3% 0.55 0.059
Control 253 1 (0) 28 (11) 224 (89) 6%
German3 Case 186 0 (0) 25 (13) 161 (87) 7% 2.23 0.038
Control 144 0 (0) 9 (6) 135 (94) 3%
Australian Case 166 0 (0) 16 (10) 150 (90) 5% 1.27 0.536
Control 169 0 (0) 13 (8) 156 (92) 4%
Replication only 1.66 0.960
Total (all of centres) 1.13 0.770
1Presented in order respective to position in DPF3; 2German discovery sample; 3German replication sample; 4Marker SNP identified in large-scale 
association study.
aNumber of subjects with genotypes; bMinor relative allele frequency; cOdds ratio for test comparing allele frequencies between cases and controls; 
dP-value for test comparing allele frequencies between cases and controls.
Fine mapping of breast cancer susceptibility on chromosome 14q24.3-q31.1 Figure 2
Fine mapping of breast cancer susceptibility on chromosome 14q24.3-q31.1. 395 SNPs in a 250-kb window were compared 
between pooled cases and controls. The x-axis corresponds to the chromosomal position and the y-axis to the test P-value 
(shown on the -log10 scale). The continuous dark line represents a goodness – of – fit test for excess of significance (compared 
to the 0.05 proportion expected by chance alone) in a 10-kb sliding window assessed at 1-kb increments. The continuous light 
grey line is the result of a non-linear smoothing function showing a weighted average of the P-values across the region. The 
shade of each point corresponds to the minor allele frequency of the corresponding SNP in the control sample (see legend 
below graph). The Entrez Gene annotation for NCBI genome build 34 is included.
Table 2: Distribution of genotype counts and relative allele frequencies of the DPF3 polymorphisms1 in breast cancer and control 
groups for discovery and replication samples. (Continued)Journal of Carcinogenesis 2005, 4:13 http://www.carcinogenesis.com/content/4/1/13
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metastases, decreased age of onset, and increased tumor
size. Our study suggests that individuals that carry one or
more G alleles of the C-to-G variant rs1990440 have a
nominally significant increase in breast cancer risk in
comparison with the CC homozygotes. This association
was substantiated in two independent collections from
Germany and Australia. Fine mapping narrowed down
the region of association to approximately 80 kb, span-
ning the majority of intron 1, exon 2 and a portion of
intron 2. Subsequent genotyping of additional SNPs iden-
tified an intron 1 SNP, rs4899445, that was more
consistently associated with breast cancer status across the
three samples (OR = 1.56, P = 0.003).
The initial marker in DPF3 was one of 74 SNPs identified
from a large-scale association study. The estimated effect
of this marker was relatively small and would have been
discounted had similar effects not been observed in the
two replication samples. Even so, the statistical signifi-
cance observed in the replication samples alone for the
marker SNP (rs1990440; P = 0.054) or the more signifi-
cant SNP identified nearby (rs4899445; P = 0.016) would
not hold up to an experiment-wide type I error rate of 0.05
after correcting for multiple testing. Given that that 74
regions followed up in replication were largely independ-
ent on a population level, a conservative Bonferroni cor-
rection would require P-values to be less than 0.0006 to
achieve the stated experiment-wide false positive rate.
Indeed, validation of these results will require a larger
sample collection. If we were to assume that the true effect
is as estimated by the replication samples (OR = 1.5) with
a population allele frequency of 6%, aggregate sample
sizes on the order of 1,000 cases and controls will be nec-
Table 3: Association of the DPF3 polymorphisms with traits of interest in discovery breast cancer cases.
Trait Genotype Estimates P-value
AA AG GG
rs4307892 G>A N N = 2 N = 59 N = 177
Age of diagnosis (Years) 235 49.654.5 59.4 45.1 54.6 60.3 51.2 56.9 63.5 0.0981
Years since diagnosis 233 4.6 8.3 12.1 0.6 2.8 5.7 0.6 2.2 5.9 0.7931
Familial breast cancer history 254 1 (50) 6 (10) 17 (10) 0.2552
Tumor size3 236 0 (0) 22 (37) 47 (28) 0.3182
Lymph node metastases (Yes) 254 2 (100) 23 (39) 46 (26) 0.0142
Organ metastases (Yes) 254 0 (0) 6 (10) 10 (6) 0.3392
GG GC CC
rs1990440 C>G N N = 2 N = 46 N = 158
Age of diagnosis (Years) 235 49.654.5 59.4 45.0 51.7 60.1 51.9 57.4 65.0 0.0121
Years since diagnosis 233 4.6 8.3 12.1 0.4 3.0 6.8 0.6 2.2 5.4 0.7621
Familial breast cancer history 254 1 (50) 6 (13) 15 (9) 0.1652
Tumor size3 236 0 (0) 20 (43) 44 (30) 0.1692
Lymph node metastases (Yes) 254 2 (100) 19 (41) 39 (25) 0.0062
Organ metastases (Yes) 254 0 (0) 6 (13) 11 (7) 0.3472
GG GA AA
rs4899445 A>G N N = 2 N = 48 N = 190
Age of diagnosis (Years) 235 49.654.5 59.4 46.4 53.8 60.6 50.6 56.5 63.3 0.3501
Years since diagnosis 233 4.6 8.3 12.1 0.7 2.8 5.7 0.6 2.3 5.9 0.7431
Familial breast cancer history 254 1 (50) 6 (12) 17 (9) 0.1322
Tumor size3 236 0 (0) 23 (48) 47 (26) 0.0072
Lymph node metastases (Yes) 254 2 (100) 20 (42) 50 (26) 0.0082
Organ metastases (Yes) 254 0 (0) 5 (10) 11 (6) 0.4152
TT TC CC
rs4378563 C>T N N = 2 N = 58 N = 175
Age of diagnosis (Years) 235 49.654.5 59.4 46.0 53.8 60.6 51.0 56.9 63.4 0.2121
Years since diagnosis 233 4.6 8.3 12.1 0.4 2.5 6.0 0.7 2.3 6.0 0.7231
Familial breast cancer history 254 1 (50) 5 (9) 16 (9) 0.2742
Tumor size3 236 0 (0) 26 (46) 43 (26) 0.0112
Lymph node metastases (Yes) 254 2 (100) 23 (40) 46 (26) 0.0132
Organ metastases (Yes) 254 0 (0) 6 (10) 10 (6) 0.3382
a ab crepresent the lower quartile a, the median b, and the upper quartile c for continuous variables. 1Kruskal-Wallis test; 2Fisher's exact test; 3T ≥ 2 
cm.Journal of Carcinogenesis 2005, 4:13 http://www.carcinogenesis.com/content/4/1/13
Page 8 of 9
(page number not for citation purposes)
essary to have adequate power to substantiate the effect of
this region on breast cancer risk.
DPF3  encodes a zinc finger protein on chromosome
14q24.3-q31.1. Zinc-fingers consist of clusters of cysteines
or cysteines and histidines that coordinately bind zinc
ions. DPF3  is a highly conserved gene homologous to
members of the d4 family of zinc-fingers. Previous
characterization of the DPF3  gene demonstrated that
while it is similar to DPF1 (neuro-d4) and DPF2 (ubi-d4/
REQ), the introns of DPF3 are much larger [30]. This fact,
in conjunction with the close similarity in the amino acid
sequences of the encoded proteins, has led to the sugges-
tion that the increase in intron size of DPF3 may result in
changes in the regulation of DPF3 gene expression. DPF3
has a C2H2 domain and a PHD domain, suggesting a role
in the direct binding of DNA and in the assembly of large
protein complexes. Functional studies of the d4 gene fam-
ily have suggested that its members participate in regula-
tion of myeloid programmed cell death through the
induction of apoptosis [31]. More recently, DPF3  has
been identified by microarray analysis as a transcription
factor that may play a role in the pathogenesis of incipient
Alzheimer's disease [32]. Publicly available information
on DPF3 gene expression is limited; however it has been
shown among others to be expressed in both normal and
cancerous breast tissue and cell lines [33].
While the current study suggests that variants in DPF3
intron 1 are associated with increased breast cancer risk,
the possible mechanism by which these variants predis-
pose to breast cancer are purely speculative. The suscepti-
bility allele might be associated with decreased DPF3
activity through the down-regulation of transcription lev-
els or by negatively impacting RNA splicing. This, in turn,
may result in a reduction in the ability of DPF3 to induce
apoptosis at the cellular level. Apoptosis is a physiological
mechanism of cell death that plays an important role in
many disease states, including cancer [34]. Imbalance of
pro-apoptotic and anti-apoptotic proteins resulting in
altered apoptosis may result in tumor development or
poor response to adjuvant therapy. Apoptosis requires de-
novo synthesis of mRNA and protein, and alterations of
DPF3 may lead to reduced response to apoptotic signal-
ing. Additional experimental studies will be required to
precisely elucidate the role of DPF3 in breast cancer etiol-
ogy and progression.
Conclusion
Our study in women of European ancestry identified sig-
nificant associations between polymorphisms in DPF3
and breast cancer susceptibility, lymph node metastases,
earlier age of onset, and tumor size. While three inde-
pendent samples from the current study support the
observed associations, additional studies are needed to
verify the results and to further characterize the gene in
order to fully understand the role of DPF3 in the etiology
and progression of breast cancer. These and similar still
undiscovered variations of small effect may be useful in
the assessment of individual breast cancer risks and in the
decisions surrounding patient care.
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